Other

4 pages, 370 KiB

Open AccessProceeding Paper

Trichinella britovi Larval Biomass in Wild Canids in the Abruzzi Region, Italy

by Pietro Badagliacca, Daria Di Sabatino, Stefania Salucci, Fabrizio De Massis, Antonio Cocco, Elga Ersilia Tieri, Gianfranco Romeo, Nicola De Dominicis, Lucilla Ricci and Antonio Petrini

Biol. Life Sci. Forum 2021, 5(1), 1; https://doi.org/10.3390/blsf2021005001 - 26 Sep 2021

Cited by 1 | Viewed by 2029

Abstract

This study estimated the larval biomass of larvae of Trichinella britovi in wild canids in annual batches of carcasses recovered from the Abruzzi region, Italy, during 2013–2020. The larval biomass decreased from about six million larvae in 2013 to less than three million [...] Read more.

This study estimated the larval biomass of larvae of Trichinella britovi in wild canids in annual batches of carcasses recovered from the Abruzzi region, Italy, during 2013–2020. The larval biomass decreased from about six million larvae in 2013 to less than three million in 2019–2020. The province of L’Aquila (99 positive specimens out of 109) was the territory most interested by Trichinella infection. As the larval biomass correlates with the larvae per gram, muscle mass and number of positive carcasses, it could be a better indicator to assess Trichinella infection in wildlife than the prevalence alone, which correlates with only positive carcasses and the examined ones. Full article

(This article belongs to the Proceedings of The XXXI National Conference of the Italian Society of Parasitology (SoIPa))

► Show Figures

Figure 1

3 pages, 165 KiB

Open AccessProceeding Paper

Registration of Novel Parasiticides under the New 2022 EU Regulation

by Sabine Richter, Julia Hunte and Klaus Hellmann

Biol. Life Sci. Forum 2021, 5(1), 2; https://doi.org/10.3390/blsf2021005002 - 11 Oct 2021

Cited by 1 | Viewed by 1287

Abstract

Twenty-one years after Directive 2001/82/EC regulating veterinary medicinal products (VMPs) came into force, a new veterinary regulation will apply from 28 January 2022. Future applicants will have to follow the requirements of Regulation (EU) 2019/6. This regulation defines different products, non-biologicals (equivalent to [...] Read more.

Twenty-one years after Directive 2001/82/EC regulating veterinary medicinal products (VMPs) came into force, a new veterinary regulation will apply from 28 January 2022. Future applicants will have to follow the requirements of Regulation (EU) 2019/6. This regulation defines different products, non-biologicals (equivalent to formerly defined pharmaceuticals), and biological products. Biological VMPs belong either to the new class, non-immunological VMPs or immunologicals, including those known as vaccines. This new regulation also defines novel therapies covering innovative medicinal therapeutic approaches. Antiparasitic products will always be VMPs, and additional requirements for environmental safety and potential risks for the development of resistance are enforced. Full article

(This article belongs to the Proceedings of The XXXI National Conference of the Italian Society of Parasitology (SoIPa))

4 pages, 224 KiB

Open AccessProceeding Paper

Prevalence and Genotyping of Pneumocystis jirovecii Pneumonia in Patients with Previously Untreated Acute Myeloid Leukemia

by Valentina Del Prete, Giovangiacinto Paterno, David Di Cave, Luca Guarnera, Raffaele Palmieri, Luca Maurillo, Francesco Buccisano, Adriano Venditti and Maria Ilaria Del Principe

Biol. Life Sci. Forum 2021, 5(1), 3; https://doi.org/10.3390/blsf2021005003 - 20 Oct 2021

Viewed by 1382

Abstract

Pneumocystis jirovecii pneumonia (PJP) is an opportunistic infection affecting immunocompromised patients. Patients with acute myeloid leukemia (AML) are not considered at high risk of PJP, thus, prophylaxis is not recommended. Between 2010 and 2020 we retrospectively analyzed 251 AML patients. We performed [...] Read more.

Pneumocystis jirovecii pneumonia (PJP) is an opportunistic infection affecting immunocompromised patients. Patients with acute myeloid leukemia (AML) are not considered at high risk of PJP, thus, prophylaxis is not recommended. Between 2010 and 2020 we retrospectively analyzed 251 AML patients. We performed molecular diagnosis and genotyping of Pneumocystis jirovecii in 67 bronchoalveolar lavage samples. Eleven cases of PJP were diagnosed, with a prevalence of 4.3%. Our study confirms that the most widespread genotype in Europe is genotype 1; in our patients, 70% presented with genotype 1 and 30% the genotype 3. Full article

(This article belongs to the Proceedings of The XXXI National Conference of the Italian Society of Parasitology (SoIPa))

3 pages, 194 KiB

Open AccessProceeding Paper

Dog Relocation and Rapidly Changing Parasite Threats

by Jason Drake

Biol. Life Sci. Forum 2021, 5(1), 4; https://doi.org/10.3390/blsf2021005004 - 25 Oct 2021

Viewed by 1323

Abstract

Dog population control methods and commercial breeding regulations have resulted in real or perceived shortages of adoptable dogs and puppies in certain geographies [...] Full article

(This article belongs to the Proceedings of The XXXI National Conference of the Italian Society of Parasitology (SoIPa))

Journal Menu

Journal Browser

Biol. Life Sci. Forum, 2021, SOIPA 2020

The XXXI National Conference of the Italian Society of Parasitology (SoIPa)

Other

Further Information

Guidelines

MDPI Initiatives

Follow MDPI